His(381) of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity

被引:33
作者
Jagerschmidt, A
GuillaumeRousselet, N
Vikland, ML
Goudreau, N
Maigret, B
Roques, BP
机构
[1] UNIV PARIS 05,FAC PHARM,UFR SCI PHARMACEUT & BIOL,URA D1500 CNRS,U266 INSERM,F-75270 PARIS 06,FRANCE
[2] UNIV NANCY 1,CHIM THEOR LAB,F-54506 VANDOEUVRE NANCY,FRANCE
关键词
CCK receptor; mutation; histidine;
D O I
10.1016/0014-2999(95)00676-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A great interest is devoted to antagonists of the cholecystokinin type B (CCKB) receptor such as L-365,260, which reduces panic attacks in humans and to antagonists of the cholecystokinin type A (CCKA) receptor, such as L-364,718 which might be efficient in mental diseases. The A/B specificity of these antagonists was proposed to be mainly dependent on the amino acid sequence of the seventh transmembrane domain (Mantamadiotis and Baldwin (1994) Biochem. Biophys. Res. Commun. 201, 1382). In our study, one of these residues, His(381) was replaced in the rat CCKB receptor by leucine (the corresponding residue in the CCKA receptor), phenylalanine or arginine using site-directed mutagenesis. Changing histidine for leucine or phenylalanine did not modify significantly the affinity of the CCKB receptor antagonists, L-365,260 and PD-134,308 although both compounds belong to different chemical classes, but strongly improved the affinity of the CCKA receptor antagonists tested. Interestingly, the A selectivity of these CCKA receptor antagonists was recovered by substituting His(381) by arginine. Moreover, these results are discussed on the basis of a three dimentional model of the CCKB receptor. The mutated receptors possessed unchanged binding properties for agonists, suggesting that determinants confering specificity for agonists and antagonists are different.
引用
收藏
页码:97 / 106
页数:10
相关论文
共 40 条
[11]  
FONG TM, 1994, J BIOL CHEM, V269, P2728
[12]  
FONG TM, 1992, J BIOL CHEM, V267, P25668
[13]  
FONG TM, 1993, NATURE, V362, P350
[14]  
FREIDINGER RM, 1989, J MED CHEM, V32, P13
[15]   AMINO-ACIDS OF THE 3RD TRANSMEMBRANE DOMAIN OF THE AT(1A) ANGIOTENSIN-II RECEPTOR ARE INVOLVED IN THE DIFFERENTIAL RECOGNITION OF PEPTIDE AND NONPEPTIDE LIGANDS [J].
GROBLEWSKI, T ;
MAIGRET, B ;
NOUET, S ;
LARGUIER, R ;
LOMBARD, C ;
BONNAFOUS, JC ;
MARIE, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 209 (01) :153-160
[16]   PERIPHERAL BIOLOGICAL-ACTIVITY OF SR-27897 - A NEW POTENT NONPEPTIDE ANTAGONIST OF CCK(A) RECEPTORS [J].
GULLY, D ;
FREHEL, D ;
MARCY, C ;
SPINAZZE, A ;
LESPY, L ;
NELIAT, G ;
MAFFRAND, JP ;
LEFUR, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 232 (01) :13-19
[17]   INTERACTION OF SUBSTANCE-P WITH THE 2ND AND 7TH TRANSMEMBRANE DOMAINS OF THE NEUROKININ-1 RECEPTOR [J].
HUANG, RRC ;
YU, H ;
STRADER, CD ;
FONG, TM .
BIOCHEMISTRY, 1994, 33 (10) :3007-3013
[18]   DEVELOPMENT OF A CLASS OF SELECTIVE CHOLECYSTOKININ TYPE-B RECEPTOR ANTAGONISTS HAVING POTENT ANXIOLYTIC ACTIVITY [J].
HUGHES, J ;
BODEN, P ;
COSTALL, B ;
DOMENEY, A ;
KELLY, E ;
HORWELL, DC ;
HUNTER, JC ;
PINNOCK, RD ;
WOODRUFF, GN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) :6728-6732
[19]  
INIS RB, 1980, P NATL ACAD SCI USA, V77, P6917
[20]  
JAGERSCHMIDT A, 1994, J NEUROCHEM, V63, P1199